Clinical trial NCT05464992: Use of CEST (Chemical Exchange Saturation Transfer) Imaging in PET/MRI
Official title: Use of CEST (Chemical Exchange Saturation Transfer) Imaging in PET/MRI
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Glioma
Brain Metastases
Lead sponsor: Institut de cancérologie Strasbourg Europe
Sponsor class: OTHER
First posted: 2022-07-19
Enrollment: 800
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Standard Magnetic Resonance Imaging (MRI) is based on the excitation of hydrogen nuclei that are presents in water molecules, which abundance in human body allows for obtention of superior contrast. However, assessing the presence of other molecules than water in tissues is also of great clinical interest to probe metabolites related to physiological body function and pathological conditions.

Chemical exchange saturation transfer (CEST) allow to overcome some limitations of proton magnetic resonance spectroscopy (1H-MRS) by exploiting chemical properties of the targeted molecule through a continuous process of re-saturation and exchange, and thus detecting it with increased sensitivity, from two orders of magnitude. Moreover, CEST technique is based on imaging sequences and can therefore benefit from well-known fast acquisition strategies, as well as improved spatial resolution.

Detailed description: For this study the investigators propose to include an additional CEST sequence in standard PET/MRI exam in order to obtain a cartography with biochemical informations from tissues in patients with glioma or brain metastases.

Eligibility criteria: Inclusion Criteria:

Patients admitted to the Nuclear Medicine and Molecular Imaging department of ICANS (Institut de cancérologie strasbourg Europe) for a PET/MRI exam dedicated to:

* Preoperative evaluation of a cerebral expansion lesion
* Evaluation of glioma recurrences
* Evaluation of brain metastases
* Evaluation of recurrence of metastases

Exclusion Criteria:

* Contraindication to the realization of an MRI
* Minor or patients placed under guardianship or supervision
* Patients deprived of liberty
* Patients placed under judicial protection
* Patients that are not able to express their consent
* Pregnant and breastfeeding women

Primary outcomes:
measure: Obtention, from a set of brain PET-MRI images, of an intratissular pH mapping in patients with glioma or brain metastases
timeFrame: through study completion, up to 14 years
measure: Obtention, from a set of brain PET-MRI images, of an intratissular pH mapping in patients with glioma or brain metastases
timeFrame: through study completion, up to 14 years
Secondary outcomes:
measure: Correlate intratissular pH mapping and location of recurrence
timeFrame: through study follow-up, up to 10 years
measure: Correlate average pH of the tumor and histopathology
timeFrame: through study follow-up, up to 10 years
measure: Correlate average pH of the tumor and Disease-Free Survival (DFS)
timeFrame: through study follow-up, up to 10 years
measure: Correlate average pH of the tumor and Overall survival (OS)
timeFrame: through study follow-up, up to 10 years
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: France Institut de cancérologie Strasbourg Europe
Study officials:
References: